{
  "ptid_time": "137_S_4815_2012-08-02",
  "img_path": "/data/qiuhui/data/adni/images/137_S_4815/2012-08-02/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 12,792 mm³, 42.7% below the reference mean. With a Z-score of -1.07 (14.2th percentile), this represents mild atrophy; hippocampal volume measures 5,111 mm³, 33.5% below the reference mean. With a Z-score of -3.76 (0.0th percentile), this represents profound atrophy; whole brain volume measures 939,334 mm³, 8.7% below the reference mean. With a Z-score of -1.09 (13.9th percentile), this represents mild atrophy; entorhinal cortex volume measures 3,269 mm³, 16.0% below the reference mean. With a Z-score of -1.24 (10.7th percentile), this represents mild atrophy; fusiform gyrus volume measures 16,369 mm³, 10.1% below the reference mean. With a Z-score of -1.14 (12.7th percentile), this represents mild atrophy; middle temporal gyrus volume measures 18,899 mm³, 7.9% below the reference mean. With a Z-score of -0.70 (24.1th percentile), this represents normal volume . ",
  "text_data": "Age is 69.8 years. Gender is Female. Education: 12 years. MMSE: 24.0. MoCA: 17.0. Logical Memory: 0.0. APOEε4 alleles: 2.0. Biomarker levels: Florbetapir (AV45): 1.58 SUVR (profound elevated); Amyloid beta: 781.30 pg/mL (normal ); Total tau: 549.20 pg/mL (profound elevated); Phosphorylated tau: 60.12 pg/mL (profound elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The patient exhibits profound hippocampal atrophy (Z-score -3.76, 0th percentile) and mild-to-moderate atrophy in other regions, alongside profoundly elevated biomarkers (T-tau, P-tau, AV45) despite normal Aβ. Cognitive scores (MMSE 24, MoCA 17) suggest significant impairment. The APOE4 homozygous status and biomarker profile strongly support Alzheimer's pathology, likely atypical (e.g., hippocampal-sparing or limbic-predominant subtype).  \n\n**Diagnosis:** **Dementia** (likely atypical Alzheimer’s disease)  \n**Confidence:** **High** (due to biomarker concordance, structural atrophy, and cognitive deficits)  \n\n*Note:* The normal Aβ is unusual but may reflect assay limitations or a non-amyloid-driven tauopathy. Further clinical correlation (e.g., FDG-PET, CSF Aβ42/40 ratio) could refine subtype classification.",
  "timestamp": "2025-07-26T16:43:19.741316"
}